4//SEC Filing
Zhou Hansheng 4
Accession 0001654954-21-001903
CIK 0001378624other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 3:13 PM ET
Size
15.3 KB
Accession
0001654954-21-001903
Insider Transaction Report
Form 4
Hansheng Zhou
Director
Transactions
- Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−5,300→ 0 totalExercise: $16.00From: 2017-07-18Exp: 2026-07-18→ Common Stock (5,300 underlying) - Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−12,056→ 0 totalExercise: $10.80From: 2018-04-28Exp: 2027-04-28→ Common Stock (12,056 underlying) - Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−7,213→ 0 totalExercise: $19.71From: 2019-04-26Exp: 2028-05-18→ Common Stock (7,213 underlying) - Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−6,019→ 0 totalExercise: $17.00From: 2020-04-24Exp: 2029-05-15→ Common Stock (6,019 underlying) - Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−6,976→ 0 totalExercise: $14.68From: 2021-04-23Exp: 2030-04-25→ Common Stock (6,976 underlying)
Footnotes (5)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among Cellular Biomedicine Group, Inc. (the "Company"), CBMG Holdings ("Parent") and CBMG Merger Sub Inc. ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the "Merger"). The Merger became effective on February 19, 2021 (the "Closing Date"). Pursuant to the Merger Agreement, at the effective time of the Merger, each stock option was cancelled and exchanged for the right to receive an amount in cash equal to (A) the total number of shares of common stock subject to such stock option multiplied by (B) the excess, if any, of the per share merger consideration of $19.75 over the exercise price of the stock option.
- [F2]As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on April 28, 2017, the Reporting Person was granted an option to purchase up to 12,056 shares of common stock, all of which vested and became fully exercisable on April 28, 2018.
- [F3]As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on April 29, 2020, on May 15, 2019, the Reporting Person was granted an option to purchase shares of common stock. These 6,019 stock options vested and became fully exercisable on April 24, 2020.
- [F4]The exercise price of this option to purchase shares of common stock was previously reported erroneously as $14.65 in the Reporting Person's Form 4 filed on April 28, 2020.
- [F5]In connection with the Merger, unvested options were accelerated and vested in full at the effective time of the Merger.
Documents
Issuer
Cellular Biomedicine Group, Inc.
CIK 0001378624
Entity typeother
Related Parties
1- filerCIK 0001679928
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 3:13 PM ET
- Size
- 15.3 KB